micro-community-banner
 
  • Saved

November 08, 2024
Emerging Myositis Treatments and Targeted Therapies – Insights from IgNS 2024

In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.

  • Saved

October 24, 2022
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary - PubMed

Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36251545/

The approval and adoption of biosimilar products are essential to contain increasing healthcare costs and provide more affordable choices for patients. Despite steady progress in the number of the United...


Conclusion: Educational efforts highlighting the rigor of the studies that support the approval of biosimilars – including the clinical pharmacology studies – and the benefits of biosimilars, can play a major role in improving biosimilar acceptance.

  • Saved

October 24, 2022
Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator

Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575662/

A TNF bio-similar might be a therapeutic option after a reaction to a TNF bio-originator. Dear Editor, Infliximab, a chimeric mAb against TNF-α, is approved for PsA treatment. Infliximab is...


Relevance: This case is interesting for two reasons. First, the patient developed an allergic reaction to one of the three different infliximab products and tolerated re-exposure with another infliximab product. Allergic reactions occur in ∼5–20% of patients treated with infliximab.

  • Saved

October 10, 2022
Oncology biosimilars: New developments and future directions - PubMed

Oncology biosimilars: New developments and future directions - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36195576/

Biologicals have become an integral part of cancer treatment both as therapeutic agents and as supportive care agents. It is important to know that biologics are large, complex molecular entities...


Conclusion/Relevance: In this review, we provide an overview of relevant legislation and regulations, pharmacoeconomics, and stakeholder perceptions regarding biosimilars. The article also describes biosimilars in development, as well as the ones currently available on the market.

  • Saved

October 10, 2022
Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease

Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527658/

Karam Elsolh, Daniel Tham, Michael A Scaffidi, MD, MEd, Nikko Gimpaya, MEd, Rishi Bansal, BArtsSc, Nazi Torabi, MLIS, Juana Li, Yash Verma, Rishad Khan, MD, and Samir C Grover, MD,...


Conclusions: Overall, we found a high burden of undisclosed conflicts among authors of PSM studies comparing IBD biologics and biosimilars. Given the importance of PSM studies as a means for biologic comparison and the potential for undue industry influence from these payments, authors should ensure greater transparency with reporting of industry relationships.